Arcutis Biotherapeutics (ARQT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $28.82, -0.96% vs the prior close of $29.10.
- Volume 1.73M shares, 0.7x its 50-day average.
- New SEC filings: 144 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
ARQT dips 1.0% to $28.82. Closed at $28.82, -0.96% vs the prior close of $29.10. Day range $28.15–$29.31, opened at $29.18.
ARQT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ARQT dips 1.0% to $28.82
- Closed at $28.82, -0.96% vs the prior close of $29.10. Day range $28.15–$29.31, opened at $29.18.
- Volume was 1.73M shares, 0.7x its 50-day average of 2.56M.
- Price is +13.1% vs its 50-day average ($25.48) and +14.9% vs its 200-day average ($25.08).
- 52-week range $19.30–$31.77; today's close sits at 76% of that range, 9.3% below the 52-week high.
Oct 15, 2026 — ARQT jumps 10.2% to $29.10, a 6-month high
- Closed at $29.10, +10.19% vs the prior close of $26.41. Day range $26.93–$29.46, opened at $26.93.
- Volume was 3.96M shares, 1.6x its 50-day average of 2.53M.
- Price is +14.4% vs its 50-day average ($25.43) and +16.1% vs its 200-day average ($25.07).
- 52-week range $19.30–$31.77; today's close sits at 79% of that range, 8.4% below the 52-week high.
Oct 14, 2026 — ARQT rises 1.2% to $26.41
- Closed at $26.41, +1.23% vs the prior close of $26.09. Day range $25.86–$26.94, opened at $26.01.
- Volume was 1.64M shares, 0.6x its 50-day average of 2.53M.
- Price is +4.0% vs its 50-day average ($25.39) and +5.3% vs its 200-day average ($25.07).
- 52-week range $19.30–$31.77; today's close sits at 57% of that range, 16.9% below the 52-week high.
Oct 13, 2026 — ARQT dips 0.5% to $26.09
- Closed at $26.09, -0.50% vs the prior close of $26.22. Day range $25.60–$26.57, opened at $25.93.
- Volume was 1.89M shares, 0.7x its 50-day average of 2.53M.
- Price is +2.8% vs its 50-day average ($25.38) and +4.0% vs its 200-day average ($25.08).
- 52-week range $19.30–$31.77; today's close sits at 54% of that range, 17.9% below the 52-week high.
Oct 12, 2026 — ARQT dips 1.4% to $26.22
- Closed at $26.22, -1.35% vs the prior close of $26.58. Day range $25.97–$26.82, opened at $26.54.
- Volume was 1.56M shares, 0.6x its 50-day average of 2.53M.
- Price is +3.3% vs its 50-day average ($25.38) and +4.5% vs its 200-day average ($25.10).
- 52-week range $19.30–$31.77; today's close sits at 56% of that range, 17.5% below the 52-week high.
Oct 9, 2026 — ARQT jumps 8.5% to $26.58, 3 up days in a row
- Closed at $26.58, +8.53% vs the prior close of $24.49. Day range $24.30–$26.97, opened at $24.50.
- Volume was 1.73M shares, 0.7x its 50-day average of 2.52M.
- Price is +4.7% vs its 50-day average ($25.39) and +5.8% vs its 200-day average ($25.11).
- 52-week range $19.30–$31.77; today's close sits at 58% of that range, 16.3% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — ARQT rises 1.3% to $24.49
- Closed at $24.49, +1.32% vs the prior close of $24.17. Day range $23.37–$24.57, opened at $23.91.
- Volume was 2.61M shares, 1.0x its 50-day average of 2.48M.
- Price is -3.7% vs its 50-day average ($25.42) and -2.6% vs its 200-day average ($25.13).
- 52-week range $19.30–$31.77; today's close sits at 42% of that range, 22.9% below the 52-week high.
Oct 7, 2026 — ARQT rises 1.0% to $24.17
- Closed at $24.17, +1.05% vs the prior close of $23.92. Day range $23.51–$24.38, opened at $23.74.
- Volume was 1.73M shares, 0.7x its 50-day average of 2.47M.
- Price is -5.2% vs its 50-day average ($25.49) and -3.9% vs its 200-day average ($25.15).
- 52-week range $19.30–$31.77; today's close sits at 39% of that range, 23.9% below the 52-week high.
Oct 6, 2026 — ARQT slides 4.9% to $23.92, 6 down days in a row
- Closed at $23.92, -4.89% vs the prior close of $25.15. Day range $23.89–$25.37, opened at $25.37.
- Volume was 2.57M shares, 1.1x its 50-day average of 2.44M.
- Price is -6.5% vs its 50-day average ($25.57) and -5.0% vs its 200-day average ($25.17).
- 52-week range $19.30–$31.77; today's close sits at 37% of that range, 24.7% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — ARQT ends flat (-0.0%) to $25.15, 5 down days in a row
- Closed at $25.15, -0.04% vs the prior close of $25.16. Day range $24.69–$25.39, opened at $25.09.
- Volume was 2.31M shares, 1.0x its 50-day average of 2.41M.
- Price is -1.9% vs its 50-day average ($25.65) and -0.2% vs its 200-day average ($25.19).
- 52-week range $19.30–$31.77; today's close sits at 47% of that range, 20.8% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — ARQT dips 0.5% to $25.16, 4 down days in a row
- Closed at $25.16, -0.51% vs the prior close of $25.29. Day range $25.01–$25.78, opened at $25.64.
- Volume was 1.78M shares, 0.7x its 50-day average of 2.40M.
- Price is -2.1% vs its 50-day average ($25.69) and -0.2% vs its 200-day average ($25.21).
- 52-week range $19.30–$31.77; today's close sits at 47% of that range, 20.8% below the 52-week high.
- That makes 4 straight losses.
ARQT latest news & SEC filings
Every SEC filing by or about ARQT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 5, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Matsuda Masaru sold 3,674 shares at $25.00 (≈$91.85K) on Sep 16, 2026; now holds 112,508
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Welgus Howard G. converted options/RSUs into 822 shares at $6.52 (≈$5.36K) on Sep 15, 2026; now holds 37,297
- Welgus Howard G. converted options/RSUs into 1,019 shares at $7.51 (≈$7.65K) on Sep 15, 2026; now holds 38,316
- Welgus Howard G. converted options/RSUs into 2,255 shares at $8.63 (≈$19.46K) on Sep 15, 2026; now holds 40,571
- Welgus Howard G. sold 4,730 shares at $24.18 (≈$114.37K) on Sep 15, 2026; now holds 35,841
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Matsuda Masaru sold 9,989 shares at $25.03 (≈$250.02K) on Sep 8, 2026
- Matsuda Masaru sold 9,989 shares at $25.03 (≈$250.02K) on Sep 8, 2026
- Matsuda Masaru sold 9,989 shares at $25.03 (≈$250.02K) on Sep 8, 2026
- Matsuda Masaru sold 9,989 shares at $25.03 (≈$250.02K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $129.86M (prior year $81.50M) (+59.3% vs Jun 30, 2025)
- Net income: $15.01M (prior year -$15.89M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.11 (prior year -$0.13) (swung to profit vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade ARQT
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: Feb 25, 2026, Oct 28, 2025, Aug 6, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.85% (largest 10.2%).
- Liquidity: about 2.25M shares (≈$64.86M) trade per day on average.
- 52-week position: $28.82 vs a range of $19.30–$31.77 (76% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Masaru Matsuda sold 3,674 shares on Sep 16, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jul 16, 2026.
- Share count: 125.69M shares outstanding (Jul 31, 2026), +4.8% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ARQT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 29.18 | 29.31 | 28.15 | 28.82 | 1.73M |
| Oct 15, 2026 | 26.93 | 29.46 | 26.93 | 29.10 | 3.96M |
| Oct 14, 2026 | 26.01 | 26.94 | 25.86 | 26.41 | 1.64M |
| Oct 13, 2026 | 25.93 | 26.57 | 25.60 | 26.09 | 1.89M |
| Oct 12, 2026 | 26.54 | 26.82 | 25.97 | 26.22 | 1.56M |
| Oct 9, 2026 | 24.50 | 26.97 | 24.30 | 26.58 | 1.73M |
| Oct 8, 2026 | 23.91 | 24.57 | 23.37 | 24.49 | 2.61M |
| Oct 7, 2026 | 23.74 | 24.38 | 23.51 | 24.17 | 1.73M |
| Oct 6, 2026 | 25.37 | 25.37 | 23.89 | 23.92 | 2.57M |
| Oct 5, 2026 | 25.09 | 25.39 | 24.69 | 25.15 | 2.31M |
| Oct 2, 2026 | 25.64 | 25.78 | 25.01 | 25.16 | 1.78M |
| Oct 1, 2026 | 26.10 | 26.43 | 25.22 | 25.29 | 1.64M |
| Sep 30, 2026 | 27.00 | 27.39 | 26.41 | 26.43 | 2.39M |
| Sep 29, 2026 | 27.21 | 27.64 | 26.73 | 26.75 | 2.94M |
| Sep 28, 2026 | 26.70 | 27.55 | 26.43 | 27.33 | 3.07M |
| Sep 25, 2026 | 26.55 | 27.09 | 25.80 | 26.92 | 2.04M |
| Sep 24, 2026 | 26.22 | 26.68 | 25.19 | 26.27 | 2.18M |
| Sep 23, 2026 | 27.79 | 28.02 | 26.07 | 26.38 | 2.51M |
| Sep 22, 2026 | 25.90 | 28.29 | 25.69 | 27.78 | 2.86M |
| Sep 21, 2026 | 25.57 | 26.08 | 25.19 | 25.96 | 1.89M |
About Arcutis Biotherapeutics
Arcutis Biotherapeutics (ARQT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WESTLAKE VILLAGE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1787306.
ARQT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Terrie Curran | Director | Aug 28, 2026 |
| Halley E Gilbert | Director | Jun 9, 2026 |
| Patrick J Heron | Director | Jun 12, 2026 |
| Neha Krishnamohan | Director | Jun 9, 2026 |
| Sue-Jean Lin | Director | Jun 17, 2026 |
| Keith R Leonard | Director | Jun 9, 2026 |
| Amit Munshi | Director | Jun 9, 2026 |
| Christopher Peetz | Director | Jul 17, 2026 |
| Todd Watanabe | See Remarks | Aug 5, 2026 |
| Howard G. Welgus | Director | Sep 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Patrick Burnett | See Remarks | Aug 21, 2026 |
| Larry Todd Edwards | See Remarks | Mar 3, 2026 |
| Masaru Matsuda | See Remarks | Sep 18, 2026 |
| Latha Vairavan | SVP Chief Financial Officer | May 13, 2026 |
| Todd Watanabe | See Remarks | Aug 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 16, 2026 | Masaru Matsuda | Sale | 3,674 | $25.00 |
| Sep 16, 2026 | Masaru Matsuda | Sale | 3,674 | $25.00 |
| Sep 16, 2026 | Masaru Matsuda | Sale | 3,674 | $25.00 |
| Sep 16, 2026 | Masaru Matsuda | Sale | 3,674 | $25.00 |
| Sep 15, 2026 | Howard G. Welgus | Sale | 4,730 | $24.18 |
| Sep 15, 2026 | Howard G. Welgus | Sale | 4,730 | $24.18 |
| Sep 15, 2026 | Howard G. Welgus | Sale | 4,730 | $24.18 |
| Sep 15, 2026 | Howard G. Welgus | Sale | 4,730 | $24.18 |
| Sep 8, 2026 | Masaru Matsuda | Sale | 9,989 | $25.03 |
| Sep 8, 2026 | Masaru Matsuda | Sale | 9,989 | $25.03 |
| Sep 8, 2026 | Masaru Matsuda | Sale | 9,989 | $25.03 |
| Sep 8, 2026 | Masaru Matsuda | Sale | 9,989 | $25.03 |
| Aug 27, 2026 | Terrie Curran | Sale | 11,148 | $25.03 |
| Aug 27, 2026 | Terrie Curran | Sale | 27,052 | $25.03 |
| Aug 27, 2026 | Terrie Curran | Sale | 11,148 | $25.03 |
ARQT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $376.07M | $-16.14M | -0.13 | $-5.62M |
| Dec 31, 2024 | $196.54M | $-140.04M | -1.16 | $-112.16M |
| Dec 31, 2023 | $59.61M | $-262.14M | -3.78 | $-247.06M |
| Dec 31, 2022 | $3.69M | $-311.46M | -5.66 | $-257.71M |
| Dec 31, 2021 | — | $-206.36M | -4.18 | $-174.63M |
Latest balance sheet: total assets $488.54M, total liabilities $267.96M, cash $34.12M (as of Jun 30, 2026).
ARQT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $27.10 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $27.01 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $24.95 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $15.36 |
| May 6, 2025 | 8-K Item 2.02 (results) | $14.32 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $12.20 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $13.63 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $9.66 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 3, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ARQT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.